

Editorial

2013 Eberhard F. Mammen Award Announcements

Emmanuel J. Favaloro, PhD, FFSc (RCPA)¹

¹ Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, New South Wales, Australia

Semin Thromb Hemost 2013;39:567–574.

Welcome to another of our Eberhard F. Mammen Award announcements. As noted previously,^{1–3} Thieme, the publisher of *Seminars in Thrombosis & Hemostasis*, has created the “Eberhard F. Mammen Excellence in Thrombosis and Hemostasis Awards” in honor of Eberhard F. Mammen (► **Fig. 1**), and in recognition of his contribution to this field and to the journal that he both founded and steered for over three decades. These awards began in 2009, under two categories:

- **Most Popular Article Awards:** The award is presented to the authors of the most popular articles published in *Seminars in Thrombosis & Hemostasis*. The awards are determined by the Editor in Chief on the basis of user statistics from Thieme eJournals from the preceding 2 years. The awards comprise two major cash prizes of US \$1,000 plus “open access” status for these articles, thereafter.
- **Young Investigator Awards:** This award is given to a young investigator with the best presentation or meeting abstract, as presented or delivered to an international or large regional meeting on a topic related to the fields of thrombosis and hemostasis, and whose subject matter is determined to be in the spirit of Dr. Mammen. There are up to six cash prizes of US \$1,000 every year. Awardees are expected to prepare a review or any other article related to the topic of their presentation for publication in *Seminars in Thrombosis & Hemostasis*.

Further details of the awards and the award winners are posted online (<http://www.thieme.com/sth>), and previous award winner announcements are also available in print.^{4–8}

It is therefore with great pleasure that I announce the latest winners of the 2013 Eberhard F. Mammen Awards, and namely those for the most popular articles from *Seminars in Thrombosis & Hemostasis* for the period of 2011–2012 as well as the Young Investigator awards related to meetings held in the recent past.

2013 Young Investigator Awards

There are six awards being granted for this category. In the past, awards were designated according to the year of the awardee's presentation, with the previous awards granted in 2012 designated as the 2011 awards. To be consistent with the most popular article awards, this will change to be identical to the year the awards are granted. Thus, these are being announced as the 2013 Young Investigator Awards. All six award winners were thrilled to hear of their awards and have agreed to prepare an article related to the topic of their presentations for a future issue of *Seminars in Thrombosis & Hemostasis*.

Four of the awardees received their award for presentations at recent American Society of Hematology (ASH) meetings, the fifth awardee received the award for a presentation at a large regional conference held in Australia, and the sixth awardee received the award for a presentation delivered at a Mayo Coagulation Quality Conference.

Vivian Xiaoyan Du (► **Fig. 2**) was granted the award because of an ASH presentation entitled “Binding of erythrocyte ICAM-4 to the platelet activated integrin $\alpha_{IIb}\beta_3$ leads to a direct erythrocyte–platelet adhesion under venous flow shear rate” and intends to write a chapter for a future issue of *Seminars in Thrombosis & Hemostasis* on “the role of red blood cells in thrombosis.” Vivian is currently a PhD candidate under the supervision of Prof. P. G. de Groot and Dr. B. de Laat at the University Medical Center, Utrecht, The Netherlands. Further information about Vivian can be found at <http://nl.linkedin.com/in/viviandu>.

Dr. Andrew Yee (► **Fig. 3**) was also granted the award because of a presentation he gave at ASH, which was entitled “Partial in vivo FVIII stabilization by VWF fragments.” His intended article for *Seminars in Thrombosis & Hemostasis* will be on “VWF: structure and function.” Dr. Andrew Yee holds a PhD in chemical engineering and is currently working as a

Address for correspondence Emmanuel J. Favaloro, PhD, FFSc (RCPA), Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, New South Wales 2145, Australia (e-mail: emmanuel.favaloro@swahs.health.nsw.gov.au).

Issue Theme Rare Bleeding Disorders: Genetic, Laboratory, Clinical, and Molecular Aspects; Guest Editor, Maha Othman, MD, PhD

Copyright © 2013 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.
Tel: +1(212) 584-4662.

DOI <http://dx.doi.org/10.1055/s-0033-1349792>.
ISSN 0094-6176.



Fig. 1 Eberhard F. Mammen (1930–2008).




Fig. 2 Vivian Xiaoyan Du, PhD Candidate.

Research Investigator at the Life Sciences Institute, University of Michigan, Ann Arbor, Michigan, on structure and function of von Willebrand Factor under the mentorship of Dr. David Ginsburg.

Dr. Sarah O'Brien (→**Fig. 4**) was also granted the award because of presentations delivered at ASH, one being related to use of bivalirudin in children with venous thromboembolism and the other assessing von Willebrand Disease in adolescents. Her intended article for *Seminars in Thrombosis & Hemostasis* will be on contraception-related thrombosis in adolescents. Dr. Sarah O'Brien is a pediatric hematologist at Nationwide Children's Hospital, Columbus, Ohio; an investigator in the Center for



Fig. 3 Dr. Andrew Yee.



Fig. 4 Dr. Sarah O'Brien.

Innovation in Pediatric Practice at Nationwide Children's Research Institute, Columbus, Ohio; and an Assistant Professor of Pediatrics at The Ohio State University College of Medicine, Columbus, Ohio. She leads a multidisciplinary hematology and adolescent gynecology clinic at Nationwide Children's Hospital. Her clinical and research interests include pediatric thrombosis and thromboprophylaxis, the evaluation and diagnosis of mild bleeding disorders, and the intersections between hematology and women's health. She has some 35 publications to her credit.

Dr. Veronica Flood (►Fig. 5) is a young hematologist who is also awarded for a presentation delivered at ASH, this being on von Willebrand Disease testing. Her intended article for *Seminars in Thrombosis & Hemostasis* will also be on the same topic. Veronica is currently employed as an Assistant Professor of pediatrics at the Division of Hematology/Oncology and as an Associate Fellowship Director, Pediatric Hematology/Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin. She has over 20 publications to her credit.

Julie Tange (►Fig. 6) spoke at the Mayo Coagulation Quality conference on issues related to verification and assignment of International Sensitivity Index (ISI) values for determination of International Normalized Ratio (INR) values across different laboratories in a large network—a particular problem in the United States because of lack of Food and Drug Administration–cleared calibration plasma sets.⁹ Julie's intended article for *Seminars in Thrombosis & Hemostasis* will also be on the same topic. Julie is currently employed as a Development Technologist at the Mayo Clinic, Special Coagulation Laboratory, Department of Laboratory Medicine and



Fig. 6 Julie Tange.

Pathology, Division of Hematopathology, Rochester, Minnesota.

Finally, Kent Chapman (►Fig. 7) was granted his award for material presented at a large Australian regional meeting comprising a conjoint scientific meeting of the Haematology Society of Australia and New Zealand, Australian and New Zealand Society of Blood Transfusion, and Australasian



Fig. 5 Dr. Veronica Flood.



Fig. 7 Kent Chapman.

Table 1 Top 50 downloaded articles from *Seminars in Thrombosis & Hemostasis* (inclusive of 2011 and 2012)

Number	Articles
1	Rak J. Microparticles in cancer. <i>Semin Thromb Hemost.</i> 2010;36(8):888–906.
2	Lippi G, Franchini M, Favaloro EJ, Targher G. Moderate red wine consumption and cardiovascular disease risk: beyond the “French paradox.” <i>Semin Thromb Hemost.</i> 2010;36(1):59–70
3	Fava C, Montagnana M, Favaloro EJ, Guidi GC, Lippi G. Obstructive sleep apnea syndrome and cardiovascular diseases. <i>Semin Thromb Hemost.</i> 2011;37(3):280–297.
4	Tufano A, Guida A, Dario Di Minno MN, Prisco D, Cerbone AM, Minno GD. Prevention of venous thromboembolism in medical patients with thrombocytopenia or with platelet dysfunction: a review of the literature. <i>Semin Thromb Hemost.</i> 2011;37(3):267–274.
5	Lacroix R, Robert S, Poncelet P, Dignat-George F. Overcoming limitations of microparticle measurement by flow cytometry. <i>Semin Thromb Hemost.</i> 2010;36(8):807–818.
6	Bitzan M, Schaefer F, Reymond D. Treatment of typical (enteropathic) hemolytic uremic syndrome. <i>Semin Thromb Hemost.</i> 2010;36(6):594–610.
7	Mariani G, Bernardi F. Factor VII deficiency. <i>Semin Thromb Hemost.</i> 2009;35(4):400–406.
8	Zoellner H. Dental infection and vascular disease. <i>Semin Thromb Hemost.</i> 2011;37(3):181–192.
9	Jurk K, Kehrel BE. Platelets: physiology and biochemistry. <i>Semin Thromb Hemost.</i> 2005;31(4):381–392.
10	Karpman D, Sartz L, Johnson S. Pathophysiology of typical hemolytic uremic syndrome. <i>Semin Thromb Hemost.</i> 2010;36(6):575–585.
11	Kose O, Zimmerhackl LB, Jungraithmayr T, Mache C, Nurnberger J. New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab. <i>Semin Thromb Hemost.</i> 2010;36(6):669–672.
12	Salmela B, Joutsu-Korhonen L, Armstrong E, Lassila R. Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis. <i>Semin Thromb Hemost.</i> 2012;38(1):23–30.
13	Tufano A, Coppola A, Cerbone AM, Ruosi C, Franchini M. Preventing postsurgical venous thromboembolism: pharmacological approaches. <i>Semin Thromb Hemost.</i> 2011;37(3):252–266.
14	Franceschi LD, Cappellini MD, Olivieri O. Thrombosis and sickle cell disease. <i>Semin Thromb Hemost.</i> 2011;37(3):226–236.
15	Lippi G, Favaloro EJ, Cervellin G. Prevention of venous thromboembolism: focus on mechanical prophylaxis. <i>Semin Thromb Hemost.</i> 2011;37(3):237–251.
16	Phang M, Lazarus S, Wood LG, Garg M. Diet and thrombosis risk: nutrients for prevention of thrombotic disease. <i>Semin Thromb Hemost.</i> 2011;37(3):199–208.
17	Pels SG. Current therapies in primary immune thrombocytopenia. <i>Semin Thromb Hemost.</i> 2011;37(6):621–630.
18	Heilmann L, Schorsch M, Hahn T, Fareed J. Antiphospholipid syndrome and pre-eclampsia. <i>Semin Thromb Hemost.</i> 2011;37(2):141–145.
19	Chapman K, Seldon M, Richards R. Thrombotic microangiopathies, thrombotic thrombocytopenic purpura, and ADAMTS-13. <i>Semin Thromb Hemost.</i> 2012;38(1):47–54.
20	Kadir RA, McIntock C. Thrombocytopenia and disorders of platelet function in pregnancy. <i>Semin Thromb Hemost.</i> 2011;37(6):640–652.
21	Favaloro EJ. Laboratory testing in disseminated intravascular coagulation. <i>Semin Thromb Hemost.</i> 2010;36(4):458–467.
22	Montagnana M, Franchi M, Danese E, Gotsch F, Guidi GC. Disseminated intravascular coagulation in obstetric and gynecologic disorders. <i>Semin Thromb Hemost.</i> 2010;36(4):404–418.
23	van der Post JA, Lok CA, Boer K, Sturk A, Sargent IL, Nieuwland R. The functions of microparticles in pre-eclampsia. <i>Semin Thromb Hemost.</i> 2011;37(2):146–152.
24	Lassila R, Antovic JP, Armstrong E, Baghaei F, Dalsgaard-Nielsen J, Hillarp A, Holme PA, Holmström M, Johnsson H, Joutsu-Korhonen L, Sandset PM. Practical viewpoints on the diagnosis and management of heparin-induced thrombocytopenia. <i>Semin Thromb Hemost.</i> 2011;37(3):328–336.
25	Franchini M, Dario Di Minno MN, Coppola A. Disseminated intravascular coagulation in hematologic malignancies. <i>Semin Thromb Hemost.</i> 2010;36(4):388–403.
26	Duntas LH, Biondi B. New insights into subclinical hypothyroidism and cardiovascular risk. <i>Semin Thromb Hemost.</i> 2011 Feb;37(1):27–34.

Table 1 (Continued)

Number	Articles
27	Flaumenhaft R, Mairuhu AT, Italiano JE. Platelet- and megakaryocyte-derived microparticles. <i>Semin Thromb Hemost.</i> 2010;36(8):881–887.
28	Zamagni E, Brioli A, Tacchetti P, Zannetti B, Pantani L, Cavo M. Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. <i>Semin Thromb Hemost.</i> 2011;37(3):209–219.
29	Schulman S, Majeed A. The oral thrombin inhibitor dabigatran: strengths and weaknesses. <i>Semin Thromb Hemost.</i> 2012;38(1):7–15.
30	Kulkarni R, Soucie JM. Pediatric hemophilia: a review. <i>Semin Thromb Hemost.</i> 2011;37(7):737–744.
31	Lyle CA, Bernard TJ, Goldenberg NA. Childhood arterial ischemic stroke: a review of etiologies, antithrombotic treatments, prognostic factors, and priorities for future research. <i>Semin Thromb Hemost.</i> 2011;37(7):786–793.
32	Karimi M, Bereczky Z, Cohan N, Muszbek L. Factor XIII Deficiency. <i>Semin Thromb Hemost.</i> 2009;35(4):426–438.
33	Breakey VR, Blanchette VS. Childhood immune thrombocytopenia: a changing therapeutic landscape. <i>Semin Thromb Hemost.</i> 2011;37(7):745–755.
34	Aatonen M, Grönholm M, Siljander PR. Platelet-derived microvesicles: multitasking participants in intercellular communication. <i>Semin Thromb Hemost.</i> 2012;38(1):102–113.
35	Franchini M, Lippi G. Factor V leiden in women: a thrombotic risk factor or an evolutionary advantage? <i>Semin Thromb Hemost.</i> 2011;37(3):275–279.
36	Duhig KE, Shennan AH. Antiplatelet agents for the prevention of pre-eclampsia. <i>Semin Thromb Hemost.</i> 2011;37(2):137–140.
37	Tan CW, Ward CM, Morel-Kopp MC. Evaluating heparin-induced thrombocytopenia: the old and the new. <i>Semin Thromb Hemost.</i> 2012;38(2):135–143.
38	Baskurt OK, Meiselman HJ. Blood rheology and hemodynamics. <i>Semin Thromb Hemost.</i> 2003;29(5):435–450.
39	Trigg DE, Wood MG, Kouides PA, Kadir RA. Hormonal influences on hemostasis in women. <i>Semin Thromb Hemost.</i> 2011;37(1):77–86.
40	Khadijah Ismail S, Higgins JR. Hemostasis in pre-eclampsia. <i>Semin Thromb Hemost.</i> 2011;37(2):111–117.
41	Emlen W, Li W, Kirschfink M. Therapeutic complement inhibition: new developments. <i>Semin Thromb Hemost.</i> 2010;36(6):660–668.
42	Kenet G, Aronis S, Berkun Y, Bonduel M, Chan A, Goldenberg NA, Holzhauer S, Iorio A, Journeycake J, Junker R, Male C, Manco-Johnson M, Massicotte P, Mesters R, Monagle P, van Ommen H, Rafini L, Simioni P, Young G, Nowak-Göttl U. Impact of persistent antiphospholipid antibodies on risk of incident symptomatic thromboembolism in children: a systematic review and meta-analysis. <i>Semin Thromb Hemost.</i> 2011;37(7):802–809.
43	Levi M, Schultz M, van der Poll T. Disseminated intravascular coagulation in infectious disease. <i>Semin Thromb Hemost.</i> 2010;36(4):367–377.
44	Chitlur M, Lusher J. Standardization of thromboelastography: values and challenges. <i>Semin Thromb Hemost.</i> 2010;36(7):707–711.
45	Jy W, Horstman LL, Ahn YS. Microparticle size and its relation to composition, functional activity, and clinical significance. <i>Semin Thromb Hemost.</i> 2010;36(8):876–880.
46	Favaloro EJ, McDonald D, Lippi G. Laboratory investigation of thrombophilia: the good, the bad, and the ugly. <i>Semin Thromb Hemost.</i> 2009;35(7):695–710.
47	de Moerloose P, Neerman-Arbez M. Congenital fibrinogen disorders. <i>Semin Thromb Hemost.</i> 2009;35(4):356–366.
48	Gonzalez E, Pieracci FM, Moore EE, Kashuk JL. Coagulation abnormalities in the trauma patient: the role of point-of-care thromboelastography. <i>Semin Thromb Hemost.</i> 2010;36(7):723–737.
49	Orth D, Wurzner R. Complement in typical hemolytic uremic syndrome. <i>Semin Thromb Hemost.</i> 2010;36(6):620–624.
50	Key NS, Mackman N. Tissue factor and its measurement in whole blood, plasma, and microparticles. <i>Semin Thromb Hemost.</i> 2010;36(8):865–875.

Society of Thrombosis and Haemostasis. Kent's intended article for *Seminars in Thrombosis & Hemostasis* will be on the same topic and will center on thrombotic thrombocytopenic purpura. Kent is a scientist with a Master's degree, currently enrolled in an AIMS (Australian Institute of Medical Scientists) fellowship program, and currently employed at the Special Coagulation Laboratory, John Hunter Hospital, New South Wales, Australia.

We offer our sincere congratulations to the six 2013 Eberhard F. Mammen Young Investigator Award winners and hope that the award encourages them to pursue continued excellence in the field of hemostasis and thrombosis throughout their career. We also look forward to read about their work in a future issue of *Seminars in Thrombosis & Hemostasis*.

2013 Most Popular Article Awards

As mentioned previously, the Most Popular Awards are given to the authors of the most popular articles published in *Seminars in Thrombosis & Hemostasis* as determined on the basis of user statistics from the publisher of this journal and covering the preceding 2-year period. Thus, the 2013 Most Popular Awards are granted to the most popular articles from 2011 to 2012 inclusive. The top 50 downloaded articles^{10–59} from this period are identified in ►Table 1.

Interestingly, the two “most popular” articles during this period were the following:

1. “Microparticles in cancer” by Rak.¹⁰
2. “Moderate red wine consumption and cardiovascular disease risk: beyond the “French paradox” by Lippi et al.¹¹

As these were the 2012 Mammen Most Popular award winning articles and were given “open access” status thereafter, they are not eligible for consideration for the 2013 award. The next two “most popular” articles during this period therefore represent the award winning articles, and these being the following:

1. “Obstructive sleep apnea syndrome and cardiovascular diseases” by Fava et al.¹²
2. “Prevention of venous thromboembolism in medical patients with thrombocytopenia or with platelet dysfunction: A review of the literature” by Tufano et al.¹³

Although I coauthored the first article, my contribution to this piece was minimal and I will also excuse myself from any personal receipt of any aspect of the award. Accordingly, I do not consider there to be any conflict of interest in the publisher of *Seminars in Thrombosis & Hemostasis* awarding the award to the lead author, Cristino Fava (►Fig. 8). The other award has been granted to Antonella Tufano (►Fig. 9). Both award winners were thrilled to hear that their articles had won the 2013 Most Popular Eberhard F. Mammen Awards, and I would convey sincere congratulations to them for this achievement.

It is also interesting (as always) to reflect on some of the other entries in the top 50, listed in ►Table 1, which relate to a



Fig. 8 Dr. Cristino Fava.



Fig. 9 Dr. Antonella Tufano.

variety of topics within the field of thrombosis and hemostasis. Of some interest, and analogous to previous years, is that some articles from previous most popular award listing have appeared yet again, and this highlights their perpetuating interest to our readership. Also of interest is that many of the articles listed are from previous Young Investigator Award Winners.^{14,21,26,28,36}

In conclusion, I would like to thank not only all of the authors listed in **Table 1**, but also the contributing authors who did not manage to make the top 50 list, as well as all the guest editors of issues recently published in *Seminars in Thrombosis & Hemostasis*.

As always, I look forward to seeing the next year's listing!

References

- Favaloro EJ. Welcome to a special issue of seminars in thrombosis and hemostasis—the closing issue for 2008. *Semin Thromb Hemost* 2008;34:693–696
- Favaloro EJ. A tribute to Eberhard F. Mammen, M.D. (1930–2008). *Semin Thromb Hemost* 2008;34(8):703–707
- Favaloro EJ. Welcome to the first issue of *Seminars in Thrombosis and Hemostasis* for 2009. *Semin Thromb Hemost* 2009;35:1–2
- Favaloro EJ. Winners of the Inaugural Eberhard F. Mammen Award for Most Popular Article. *Semin Thromb Hemost* 2009;35:587–590
- Favaloro EJ. 2009 Eberhard F. Mammen Young Investigator Award winners. *Semin Thromb Hemost* 2010;36:469–470
- Favaloro EJ. Winners of the 2010 Eberhard F. Mammen award for most popular article during 2008–2009. *Semin Thromb Hemost* 2010;36(7):685–692
- Favaloro EJ. 2011 Eberhard F. Mammen Award announcements. *Semin Thromb Hemost* 2011;37(5):431–439
- Favaloro EJ. 2012 Eberhard F. Mammen Award announcements. *Semin Thromb Hemost* 2012;38:425–432
- Favaloro EJ, Plebani M, Lippi G. Regulation in hemostasis and thrombosis: part I—in vitro diagnostics. *Semin Thromb Hemost* 2013;39(3):235–249
- Rak J. Microparticles in cancer. *Semin Thromb Hemost* 2010;36(8):888–906
- Lippi G, Franchini M, Favaloro EJ, Targher G. Moderate red wine consumption and cardiovascular disease risk: beyond the “French paradox”. *Semin Thromb Hemost* 2010;36(1):59–70
- Fava C, Montagnana M, Favaloro EJ, Guidi GC, Lippi G. Obstructive sleep apnea syndrome and cardiovascular diseases. *Semin Thromb Hemost* 2011;37(3):280–297
- Tufano A, Guida A, Di Minno MN, Prisco D, Cerbone AM, Di Minno G. Prevention of venous thromboembolism in medical patients with thrombocytopenia or with platelet dysfunction: a review of the literature. *Semin Thromb Hemost* 2011;37(3): 267–274
- Lacroix R, Robert S, Poncelet P, Dignat-George F. Overcoming limitations of microparticle measurement by flow cytometry. *Semin Thromb Hemost* 2010;36(8):807–818
- Bitzan M, Schaefer F, Reymond D. Treatment of typical (enteropathic) hemolytic uremic syndrome. *Semin Thromb Hemost* 2010;36(6):594–610
- Mariani G, Bernardi F. Factor VII Deficiency. *Semin Thromb Hemost* 2009;35(4):400–406
- Zoellner H. Dental infection and vascular disease. *Semin Thromb Hemost* 2011;37(3):181–192
- Jurk K, Kehrel BE. Platelets: physiology and biochemistry. *Semin Thromb Hemost* 2005;31(4):381–392
- Karpman D, Sartz L, Johnson S. Pathophysiology of typical hemolytic uremic syndrome. *Semin Thromb Hemost* 2010;36(6):575–585
- Köse O, Zimmerhackl LB, Jungraithmayr T, Mache C, Nürnberger J. New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab. *Semin Thromb Hemost* 2010;36(6):669–672
- Salmela B, Joutsen-Korhonen L, Armstrong E, Lassila R. Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis. *Semin Thromb Hemost* 2012;38(1):23–30
- Tufano A, Coppola A, Cerbone AM, Ruosi C, Franchini M. Preventing postsurgical venous thromboembolism: pharmacological approaches. *Semin Thromb Hemost* 2011;37(3):252–266
- De Franceschi L, Cappellini MD, Olivieri O. Thrombosis and sickle cell disease. *Semin Thromb Hemost* 2011;37(3):226–236
- Lippi G, Favaloro EJ, Cervellini G. Prevention of venous thromboembolism: focus on mechanical prophylaxis. *Semin Thromb Hemost* 2011;37(3):237–251
- Phang M, Lazarus S, Wood LG, Garg M. Diet and thrombosis risk: nutrients for prevention of thrombotic disease. *Semin Thromb Hemost* 2011;37(3):199–208
- Pels SG. Current therapies in primary immune thrombocytopenia. *Semin Thromb Hemost* 2011;37(6):621–630
- Heilmann L, Schorsch M, Hahn T, Fareed J. Antiphospholipid syndrome and pre-eclampsia. *Semin Thromb Hemost* 2011;37(2):141–145
- Chapman K, Seldon M, Richards R. Thrombotic microangiopathies, thrombotic thrombocytopenic purpura, and ADAMTS-13. *Semin Thromb Hemost* 2012;38(1):47–54
- Kadir RA, McLintock C. Thrombocytopenia and disorders of platelet function in pregnancy. *Semin Thromb Hemost* 2011;37(6): 640–652
- Favaloro EJ. Laboratory testing in disseminated intravascular coagulation. *Semin Thromb Hemost* 2010;36(4):458–467
- Montagnana M, Franchi M, Danese E, Gotsch F, Guidi GC. Disseminated intravascular coagulation in obstetric and gynecologic disorders. *Semin Thromb Hemost* 2010;36(4):404–418
- van der Post JA, Lok CA, Boer K, Sturk A, Sargent IL, Nieuwland R. The functions of microparticles in pre-eclampsia. *Semin Thromb Hemost* 2011;37(2):146–152
- Lassila R, Antovic JP, Armstrong E, et al. Practical viewpoints on the diagnosis and management of heparin-induced thrombocytopenia. *Semin Thromb Hemost* 2011;37(3):328–336
- Franchini M, Di Minno MN, Coppola A. Disseminated intravascular coagulation in hematologic malignancies. *Semin Thromb Hemost* 2010;36(4):388–403
- Duntas LH, Biondi B. New insights into subclinical hypothyroidism and cardiovascular risk. *Semin Thromb Hemost* 2011;37(1): 27–34
- Flaumenhaft R, Mairuhu AT, Italiano JE. Platelet- and megakaryocyte-derived microparticles. *Semin Thromb Hemost* 2010;36(8):881–887
- Zamagni E, Brioli A, Tacchetti P, Zannetti B, Pantani L, Cavo M. Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. *Semin Thromb Hemost* 2011;37(3):209–219
- Schulman S, Majeed A. The oral thrombin inhibitor dabigatran: strengths and weaknesses. *Semin Thromb Hemost* 2012;38(1): 7–15
- Kulkarni R, Soucie JM. Pediatric hemophilia: a review. *Semin Thromb Hemost* 2011;37(7):737–744
- Lyle CA, Bernard TJ, Goldenberg NA. Childhood arterial ischemic stroke: a review of etiologies, antithrombotic treatments, prognostic factors, and priorities for future research. *Semin Thromb Hemost* 2011;37(7):786–793
- Karimi M, Bereczky Z, Cohan N, Muszbek L. Factor XIII Deficiency. *Semin Thromb Hemost* 2009;35(4):426–438
- Breakley VR, Blanchette VS. Childhood immune thrombocytopenia: a changing therapeutic landscape. *Semin Thromb Hemost* 2011;37(7):745–755

- 43 Aatonen M, Grönholm M, Siljander PR. Platelet-derived microvesicles: multitasking participants in intercellular communication. *Semin Thromb Hemost* 2012;38(1):102–113
- 44 Franchini M, Lippi G. Factor V Leiden in women: a thrombotic risk factor or an evolutionary advantage? *Semin Thromb Hemost* 2011;37(3):275–279
- 45 Duhig KE, Shennan AH. Antiplatelet agents for the prevention of pre-eclampsia. *Semin Thromb Hemost* 2011;37(2):137–140
- 46 Tan CW, Ward CM, Morel-Kopp MC. Evaluating heparin-induced thrombocytopenia: the old and the new. *Semin Thromb Hemost* 2012;38(2):135–143
- 47 Baskurt OK, Meiselman HJ. Blood rheology and hemodynamics. *Semin Thromb Hemost* 2003;29(5):435–450
- 48 Trigg DE, Wood MG, Kouides PA, Kadir RA. Hormonal influences on hemostasis in women. *Semin Thromb Hemost* 2011;37(1):77–86
- 49 Ismail SK, Higgins JR. Hemostasis in pre-eclampsia. *Semin Thromb Hemost* 2011;37(2):111–117
- 50 Emlen W, Li W, Kirschfink M. Therapeutic complement inhibition: new developments. *Semin Thromb Hemost* 2010;36(6):660–668
- 51 Kenet G, Aronis S, Berkun Y, et al. Impact of persistent antiphospholipid antibodies on risk of incident symptomatic thromboembolism in children: a systematic review and meta-analysis. *Semin Thromb Hemost* 2011;37(7):802–809
- 52 Levi M, Schultz M, van der Poll T. Disseminated intravascular coagulation in infectious disease. *Semin Thromb Hemost* 2010;36(4):367–377
- 53 Chitlur M, Lusher J. Standardization of thromboelastography: values and challenges. *Semin Thromb Hemost* 2010;36(7):707–711
- 54 Jy W, Horstman LL, Ahn YS. Microparticle size and its relation to composition, functional activity, and clinical significance. *Semin Thromb Hemost* 2010;36(8):876–880
- 55 Favaloro EJ, McDonald D, Lippi G. Laboratory investigation of thrombophilia: the good, the bad, and the ugly. *Semin Thromb Hemost* 2009;35(7):695–710
- 56 de Moerloose P, Neerman-Arbez M. Congenital fibrinogen disorders. *Semin Thromb Hemost* 2009;35(4):356–366
- 57 Gonzalez E, Pieracci FM, Moore EE, Kashuk JL. Coagulation abnormalities in the trauma patient: the role of point-of-care thromboelastography. *Semin Thromb Hemost* 2010;36(7):723–737
- 58 Orth D, Würzner R. Complement in typical hemolytic uremic syndrome. *Semin Thromb Hemost* 2010;36(6):620–624
- 59 Key NS, Mackman N. Tissue factor and its measurement in whole blood, plasma, and microparticles. *Semin Thromb Hemost* 2010;36(8):865–875